Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia

REFERENCES

• PERRY DJ: Hyperhomocysteinaemia. BaMere's Best Practise (1999) 3:451–477.
   Google Scholar
• MINOR SE, EVROVSKI J, COLE DE: Clinical chemistry and molecular biology of homocysteine metabolism: an update. Clin. Biochem. (1997) 30:189–201.
   PubMedGoogle Scholar
• DUDMAN NP, GUO XW, GORDON RB, DAWSON PA, WILCKEN DE: Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. J. Num (1996) 126:1295–1300.
   Google Scholar
• D'ANGELO A, SELHUB J: Homocysteine and thrombotic disease. Blood (1997) 90:1–11.
   PubMed Web of Science ®Google Scholar
• HANKEY GJ, EIKELBOOM JW: Homocysteine and vascular disease. Lancet (1999) 354:407–413.
   PubMed Web of Science ®Google Scholar
• MCCULLEY KS: Homocysteine and vascular disease. Nat. Med. (1996) 2:368–389.
   Google Scholar
• MALINOW MR, DUELL PB, HESS DL et al.: Reduction of plasma homocyst(e)ine levels by breakfast fortified with folic acid in patients with coronary heart disease. N Engl. J. Med. (1998) 338:1009–1015.
   PubMed Web of Science ®Google Scholar
• ISHERWOOD DM: Homocystinuria. BL Med. J. (1996) 313:1025–1026.
   PubMedGoogle Scholar
• KANG SS, WONG PW, NORUSSIS M: Homocysteinemia due to folate deficiency. Metabolism (1997) 36:458–462.
   Google Scholar
• FOWLER B: Genetic defects of folate and cobalamin metabolism. Ear: Pediatr. (1998) 157:S60–S66.
   Google Scholar
• VAN GULDENER C, ROBINSON K: Homocysteine and renal disease. Sem. Thromb. Haemost. (2000) 26:313–324.
   PubMedGoogle Scholar
• SELHUB J, JACQUES PF, WILSON PW, RUSH D, ROSENBERG IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. "AMA (1993) 270:2693–2698.
   PubMed Web of Science ®Google Scholar
• FROSST P, BLOM HJ, MILOS R et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. (1995) 10:111–113.
   PubMed Web of Science ®Google Scholar
• SHIP CHANDLER MT, MOORE EG: Rapid fully automated measurement of plasma homocyst(e)ine with the Abbott Imx analyser. Gin. Chem. (1995) 41:991–994.
   Google Scholar
• CATTANEO M, MARTINEELLI I, MANNUCCI PM: Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl. J. Med. (1996) 335:975–976.
   PubMedGoogle Scholar
• McCULLY KS: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am. .1 Pathol (1969) 56:111–128.
   Google Scholar
• BOERS GH, SMOLS AG, TRIJBELS FJ: Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl. J. Med. (1985) 313:709–715.
   PubMed Web of Science ®Google Scholar
• BOUSHEY CJ, BERESFORD SA, OMENN GS, MOTULSKY AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefit of increasing folic acid intakes. "AMA (1995) 274:1049–1057.
   Google Scholar
• STAMPFER MJ, MALINOW R, WILLETT WC et al: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. "AMA (1992) 268:877–881.
   PubMed Web of Science ®Google Scholar
• ARNESEN E, REFSUM H, BONAA KH, UELAND PM, FORDE OH, NORDREHAUG JE: Serum total homocysteine and coronary heart disease. Int. J. Epidemiol (1995) 24:704–708.
   PubMed Web of Science ®Google Scholar
• CHRISTEN WG, AJANI UA, GLYNN RJ,HENNEKENS CH: Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual?Arch. Intern. Med. (2000) 160:422–434.
   Web of Science ®Google Scholar
• CLEOPHAS TJ, HORNSTRA N, VAN HOOGSTRATEN B, VAN DER MEULEN J: Homocysteine, a risk factor for coronary heart disease or not? A meta-analysis. Am. J. Cardiol (2000) 86:1005–1009.
   PubMedGoogle Scholar
• KNEKT P, REUNANEN A, ALFTHAN G et al.: Hyperhomocystinemia: a risk factor or a consequence of coronary heart disease? Arch. Intern. Med. (2001) 161:1589–1594.
   Google Scholar
• DEN HEUER M, KOSTER T, BLOM HJ et al.: Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl. J. Med. (1996) 334:759–762.
   PubMedGoogle Scholar
• D'ANGELO A, MAZZOLA G, CRIPPA L,FERMO I, VIGANO D'ANGELO S: Hyperhomocysteinemia and venous thromboembolic disease. Haematologica (1997) 82:211–219.
   PubMedGoogle Scholar
• RIDKER PM, HENNEKENS CH, SELHUB J: Interrelation of hyperhomocysteinemia, Factor V Leiden, and risk of future venous thromboembolism. Circulation (1997) 95:1777–1782.
   PubMed Web of Science ®Google Scholar
• TOWNSEND J, O'SULLIVAN J, WILDEJT: Hyperhomocysteinaemia and vascular disease. Blood Rev (1998) 12:23–34.
   PubMedGoogle Scholar
• CLARKE R, ARMITAGE J: Vitamin supplements and cardiovascular risk: review of the randomised trials of homocysteine-lowering vitamin supplements. Sem. Thromb. Haemost. (2000) 26:341–348.
   PubMed Web of Science ®Google Scholar
• DEN HEUER M, BROUWER IA, BOS GMJ et al.: Vitamin supplementation reduces blood homocysteine levels. Arteriosci. DIF017111. V3SC. Biol. (1998) 18:356–361.
   Google Scholar
• NAURATH HJ, JOOSTEN E, RIEZLER R, STABLER SP, ALLEN RH, LINDENBAUM J: Effects of vitamin B12, folate and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet (1995) 346:85–89.
   PubMed Web of Science ®Google Scholar
• CLARKE R: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br. Med. J. (1998) 316:894–898.
   PubMedGoogle Scholar
• MALINOW MR, NIETO FJ, KRUGER WD et al.: The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscl. Thromb. Vasc. Biol. (1997) 17:1157–1162.
   PubMed Web of Science ®Google Scholar
• ASHFIELD-WATT PA, PULLIN CH, WHITING JM et al.: Methylenetetrahydrofolate reductase 677C T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. Am. I. Gin. Num. (2002) 76:180–186.
   PubMed Web of Science ®Google Scholar
• JACQUES PF, BOSTOM AG, WILLIAMS RR et al.: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase and plasma homocysteine concentrations. Circulation (1996) 93:7–9.
   PubMed Web of Science ®Google Scholar
• LINDENBAUM J, HEALTON EB, SAVAGE DG et al: Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anaemia or macrocytosis. N. Engl. J. Med. (1998) 318:1720–1728.
   Google Scholar
• WILCKEN DE, WILCKEN B, DUDMAN NP, TYRRELL PA: Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl. I Med. (1983) 309:448–453.
   PubMed Web of Science ®Google Scholar
• WILCKEN DEL, DUDMAN NPB, TYRELL PA: Homocystinuria due to cystathione 13-synthase deficiency - the effects of betaine treatment in pyridoxine-responsive patients. Metabolism (1985) 34:1115–1121.
   PubMedGoogle Scholar
• VENTURA P, PANINI R, PASINI MC, SCARPETTA G, SALVIOLI G: N-Actyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol. Res. (1999) 40:345–350.
   PubMed Web of Science ®Google Scholar
• HUSSEIN WI, GREEN R, JACOBSEN DW, FAIMAN C: Normalization of hyperhomocysteinemia with L-thyroxine in hypothyroidism. Ann. Intern. Med. (1999) 131:348–351.
   PubMed Web of Science ®Google Scholar
• BROUWER IA, VAN DUSSEDORP M, WEST CE: Dietary folate from vegetables and citrus fruits decreases plasma homocysteine concentrations in humans in a controlled trial.,/ Num. (1999) 129:1135–1139.
   Google Scholar
• RIDDELL LJ, CHISHOLM A, WILLIAMS S, MANN JI: Dietary strategies for lowering homocysteine concentrations. Am. Clin. Num. (2000) 71:1448–1454.
   PubMed Web of Science ®Google Scholar
• LAW M: Fortifying food with folic acid. Sem. Thromb. Haemost. (2000) 26:349–352.
   PubMedGoogle Scholar
• DALY LE, KIRKE PN, MOLLOY A, WEIR DG, SCOTT JM: Folate levels and neural tube defects. Implications for prevention. JAMA (1995) 274:1698–1702.
   Google Scholar
• WALD NJ, LAW M, JORDAN R: Folic acid food fortification to prevent neural tube defects. Lancet (1998) 351:834.
   PubMed Web of Science ®Google Scholar
• CAMBELL NRC. How safe are folic acid supplements? Arch. Intern. Med. (1996) 156:1638–1644.
   Google Scholar
• CUSKELLY GJ, MCNULTY H, SCOTT JM: Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. Lancet (1996) 347:657–659.
   PubMed Web of Science ®Google Scholar
• MALINOW MR, DUELL PB, HESS DL et al.: Reduction of plasma homocyst(e)ine by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl. Med. (1998) 338:1009–1015.
   PubMed Web of Science ®Google Scholar
• PFEIFFER CM, ROGERS LM, BAILEY LB, GREGORY JF III: Absorption of folate from fortified cereal-grain products and of supplemental folate consumed with or without food determined by using a dual-label stable isotope protocol. Am. Num (1997) 66:1388–1397.
   PubMed Web of Science ®Google Scholar
• YAP S, NAUGHTEN ER, WILCKEN B, WILCKEN DEL, BOERS GHJ: Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathione synthetase deficiency: Effects of homocysteine-lowering therapy. Sem. Thromb. Haemost. (2000) 26:335–340.
   PubMed Web of Science ®Google Scholar
• MUDD SH, SKOVBY F, LEVY HL et al:The natural history of homocystinuria due to cystathionine 13-synthase deficiency. Am.j Hum. Genet. (1985) 37:571–S76.
   Google Scholar
• WALTER JH, WRAITH JE, WHITE FJ,BRIDGE C, TILL J: Strategies for the treatment of P-synthetase deficiency: the experience of the Willnick Biochemical Genetics Unit over the past 30 years. Eur: Pediam. (1998) 157:S71–S76.
   Google Scholar
• PERNA AF, INGROSSO D, DE SANTO NG, GALLETTI P, BRUNONE M, ZAPPIA V: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia.' Am. Soc. Nephrol. (1997) 8: 1899-1905.
   Google Scholar
• ROBINSON K, GUPTA A, DENNIS V et al.: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation (1996) 94:2743–2748.
   PubMedGoogle Scholar
• ARNADOTTIR M, BERG AL, HEGBRANT J, HULTENBERG B: Influence of haemodialysis on plasma total homocysteine concentration. Nephrol. Dial. Transplant. (1999) 14:142–146.
   PubMed Web of Science ®Google Scholar
• ARNADOTTIR M, HULTENBERG B, VLADOV V, NILSSON-EHLE P, THYSELL H: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation (1996) 61:509–512.
   PubMed Web of Science ®Google Scholar
• ARNADOTTIR M, BRATTSTROM L, SIMONSEN 0 et al.: The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin. Nephrol. (1993) 40:236–240.
   Google Scholar
• BOSTOM AG, SHEMIN D, LAPANE KU et al.: High-dose B-vitamin treatment of hyperhomocyteinemia in dialysis patients. Kidney Int. (1996) 49:147–152.
   PubMed Web of Science ®Google Scholar
• TOUAM M, ZINGRAFF J, JUNGERS P, CHADEFAUX-VEKEMANS B, DRUEKE T, MASSY ZA: Effective correction of hyperhomocysteinemia in hemodialysis by intravenous folinic acid and pyridoxine therapy. Kidney bit. (1999) 56:2292–2296.
   PubMed Web of Science ®Google Scholar
• BUCCIANTI G, BAMONTI CATENA F, PATROSSO C et al: Reduction of the homocysteine plasma concentration by intravenously administered folinic acid and vitamin B(12) in uraemic patients on maintenance haemodialysis. Am.' Nephrol. (2001) 21:294–299.
   PubMed Web of Science ®Google Scholar